Should You Buy McKesson Corp (MCK) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Buy
Latest Price
826.620
1 Day change
-0.91%
52 Week Range
895.580
Analysis Updated At
2026/01/26
McKesson Corp (MCK) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company demonstrates strong financial performance, positive sentiment from analysts, and favorable congressional trading activity. Despite neutral technical indicators, the stock's long-term growth prospects and positive catalysts make it a solid choice for long-term investment.
Technical Analysis
The technical indicators are neutral. The MACD is negatively expanding below zero, suggesting bearish momentum. RSI is at 42.362, indicating no overbought or oversold conditions. Moving averages are converging, showing no clear trend. Key support is at 811.569, and resistance is at 842.816.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Technical Summary
Sell
4
Buy
7
Positive Catalysts
Strong financial performance in Q2 2026, with revenue up 10.14% YoY, net income up 360.58% YoY, and EPS up 379.57% YoY.
Positive congressional trading activity with 4 purchase transactions and no sales in the last 90 days.
Analysts have raised price targets significantly, with multiple buy and outperform ratings.
The company plans to exit its med-surgical business, which could unlock value in the long term.
Neutral/Negative Catalysts
Technical indicators are neutral, with no clear bullish signals.
The MACD is negatively expanding, suggesting short-term bearish momentum.
No recent news or significant hedge fund/insider trading trends.
Financial Performance
In Q2 2026, McKesson reported revenue of $103.15B (up 10.14% YoY), net income of $1.11B (up 360.58% YoY), and EPS of $8.92 (up 379.57% YoY). Gross margin increased to 3.43%, up 0.88% YoY. These results indicate strong growth and operational efficiency.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Analysts are highly positive on McKesson, with multiple firms raising price targets recently. Deutsche Bank raised its target to $904, Barclays initiated coverage with a $960 target, and TD Cowen and Evercore ISI set targets at $1,000. The consensus reflects strong confidence in the company's growth prospects.
Wall Street analysts forecast MCK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MCK is 942.83 USD with a low forecast of 880 USD and a high forecast of 1000 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast MCK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MCK is 942.83 USD with a low forecast of 880 USD and a high forecast of 1000 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
2 Hold
0 Sell
Strong Buy
Current: 834.180
Low
880
Averages
942.83
High
1000
Current: 834.180
Low
880
Averages
942.83
High
1000
Deutsche Bank
George Hill
Buy
maintain
$861 -> $904
AI Analysis
2025-12-10
Reason
Deutsche Bank
George Hill
Price Target
$861 -> $904
AI Analysis
2025-12-10
maintain
Buy
Reason
Deutsche Bank analyst George Hill raised the firm's price target on McKesson to $904 from $861 and keeps a Buy rating on the shares. The company reiterated plans to exit the its med-surgical business segment through an initial public offering, followed by a spin-off or split-off, with the separation being complete by the end of 2027, the analyst tells investors in a research note. The firm says that while the transaction is likely dilutive, the stock "can still perform through the transaction."
Barclays
Overweight
initiated
$960
2025-12-08
Reason
Barclays
Price Target
$960
2025-12-08
initiated
Overweight
Reason
Barclays initiated coverage of McKesson with an Overweight rating and $960 price target. The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MCK
